Published preclinical results confirm IdeS potential in cancer immunotherapy
Hansa Medical AB (publ), a biopharmaceutical company developing novel immunomodulatory enzymes, announced today that preclinical data have been published in the peer-reviewed journal, Molecular Cancer Therapeutics (Järnum et al., Mol Cancer Ther May 22 2017 DOI: 10.1158/1535-7163.MCT-17-0108), confirming the potential of the company’s lead candidate IdeS in cancer immunotherapy.The published findings demonstrate how pre-treatment with IdeS in tumour animal models can increase the efficacy of currently available antibody based cancer therapies. Christian Kjellman, Senior Vice President R&
